ID   OCUT-2
AC   CVCL_9814
SY   OCUT2; Osaka City University Thyroid-2
DR   BTO; BTO_0005143
DR   cancercelllines; CVCL_9814
DR   Cosmic; 1507373
DR   Cosmic; 1533549
DR   Cosmic; 1536126
DR   Cosmic; 1889004
DR   Cosmic; 2791082
DR   JCRB; JCRB1870
DR   Wikidata; Q54931846
RX   PubMed=15785737;
RX   PubMed=24357248;
RX   PubMed=26137260;
RX   PubMed=30737244;
CC   Population: Japanese.
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=24357248; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=24357248).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Homozygous; Note=In promoter (PubMed=30737244).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): JCRB=JCRB1870; PubMed=30737244
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11
ST   D16S539: 9
ST   D18S51: 13
ST   D21S11: 30,32.2
ST   D3S1358: 15
ST   D5S818: 13
ST   D7S820: 11
ST   D8S1179: 13,14
ST   FGA: 21,26
ST   TH01: 6,7
ST   TPOX: 11
ST   vWA: 14,18
DI   NCIt; C3878; Thyroid gland anaplastic carcinoma
DI   ORDO; Orphanet_142; Anaplastic thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   81Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 19
//
RX   PubMed=15785737; DOI=10.1038/sj.bjc.6602461; PMCID=PMC2361935;
RA   Nobuhara Y., Onoda N., Yamashita Y., Yamasaki M., Ogisawa K.,
RA   Takashima T., Ishikawa T., Hirakawa K.;
RT   "Efficacy of epidermal growth factor receptor-targeted molecular
RT   therapy in anaplastic thyroid cancer cell lines.";
RL   Br. J. Cancer 92:1110-1116(2005).
//
RX   PubMed=24357248; DOI=10.1007/s00268-013-2409-7;
RA   Onoda N., Nakamura M., Aomatsu N., Noda S., Kashiwagi S., Hirakawa K.;
RT   "Establishment, characterization and comparison of seven authentic
RT   anaplastic thyroid cancer cell lines retaining clinical features of
RT   the original tumors.";
RL   World J. Surg. 38:688-695(2014).
//
RX   PubMed=26137260; DOI=10.3892/mco.2015.496; PMCID=PMC4471583;
RA   Onoda N., Nakamura M., Aomatsu N., Noda S., Kashiwagi S., Kurata K.,
RA   Uchino S., Hirakawa K.;
RT   "Significant cytostatic effect of everolimus on a gefitinib-resistant
RT   anaplastic thyroid cancer cell line harboring PI3KCA gene mutation.";
RL   Mol. Clin. Oncol. 3:522-526(2015).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//